Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.

Frontiers in immunology

Oberg HH, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D.
PMID: 25566256
Front Immunol. 2014 Dec 17;5:643. doi: 10.3389/fimmu.2014.00643. eCollection 2014.

The success of γδ T cell-based immunotherapy, where the cytotoxic activity of circulating γδ T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients' γδ...

Cite
Oberg HH, Kellner C, Peipp M, et al. Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy. Front Immunol. 2014;5:643doi: 10.3389/fimmu.2014.00643.
Oberg, H. H., Kellner, C., Peipp, M., Sebens, S., Adam-Klages, S., Gramatzki, M., Kabelitz, D., & Wesch, D. (2014). Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy. Frontiers in immunology, 5643. https://doi.org/10.3389/fimmu.2014.00643
Oberg, Hans-Heinrich, et al. "Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy." Frontiers in immunology vol. 5 (2014): 643. doi: https://doi.org/10.3389/fimmu.2014.00643
Oberg HH, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D. Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy. Front Immunol. 2014 Dec 17;5:643. doi: 10.3389/fimmu.2014.00643. eCollection 2014. PMID: 25566256; PMCID: PMC4269191.
Copy Download .nbib Format: NLM
Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration.

Cell communication and signaling : CCS

Koop A, Sellami N, Adam-Klages S, Lettau M, Kabelitz D, Janssen O, Heidebrecht HJ.
PMID: 23758873
Cell Commun Signal. 2013 Jun 10;11(1):41. doi: 10.1186/1478-811X-11-41.

BACKGROUND: Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was associated with a severe disease...

Cite
Koop A, Sellami N, Adam-Klages S, et al. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal. 2013;11(1):41doi: 10.1186/1478-811X-11-41.
Koop, A., Sellami, N., Adam-Klages, S., Lettau, M., Kabelitz, D., Janssen, O., & Heidebrecht, H. J. (2013). Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell communication and signaling : CCS, 11(1), 41. https://doi.org/10.1186/1478-811X-11-41
Koop, Anja, et al. "Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration." Cell communication and signaling : CCS vol. 11,1 (2013): 41. doi: https://doi.org/10.1186/1478-811X-11-41
Koop A, Sellami N, Adam-Klages S, Lettau M, Kabelitz D, Janssen O, Heidebrecht HJ. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal. 2013 Jun 10;11(1):41. doi: 10.1186/1478-811X-11-41. PMID: 23758873; PMCID: PMC3689639.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries